Read more about the article @AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue Reading@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article @AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue Reading@AllogeneTx: Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue ReadingToday we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article @AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue Reading@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we're proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!
Read more about the article @AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue Reading@AllogeneTx: Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology!
Read more about the article Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology! https://t.co/KxtmUr2wPZ

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology! https://t.co/KxtmUr2wPZ

Congrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang,…

Continue ReadingCongrats to our co-founder Dr. @Arie_Belldegrun in @endpts “60 over 60”, along with friends Vicki Sato, Ph.D. and Dr. Steven Rosenberg. With a special mention for our CEO David Chang, we’re proud of the rich legacies our co-founders and advisors bring to Allogene and oncology! https://t.co/KxtmUr2wPZ
Read more about the article @AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

@AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue Reading@AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO
Read more about the article @AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

@AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue Reading@AllogeneTx: Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO
Read more about the article Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue ReadingPlease join us for an update on our AlloCAR T™ platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO
Read more about the article @AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue Reading@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO